Financial PerformanceGross margins expanded to 67.3% from 66.6% y/y and operating margins to 26.1% from 25.5%, delivering EPS ahead of consensus.
Market ShareManagement expects growth to accelerate with CVI at least in line with the broader contact lens market and with CSI gaining share.
Strategic AlternativesThe evaluation of strategic alternatives, including the separation of its Contact Lens and Women’s Health businesses, is seen as potentially value creative for investors.